GlassScriptPhysician profile
Rena Montgomery
NPI 1871728436
$3,797.28
in general payments reported to CMS, 2019-2025
29 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,085 · 2022: $727 · 2023: $679 · 2024: $302 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.26 |
| Education | $152.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $807.91 | 2021-2025 | Veozah |
| Mayne Pharma Commercial LLC | $299.81 | 2023-2025 | |
| Novo Nordisk INC | $265.57 | 2023-2025 | Wegovy, Saxenda |
| Revance Therapeutics, INC. | $254.27 | 2025 | Daxxify |
| Amgen INC. | $213.71 | 2021-2022 | |
| Exeltis, USA INC. | $184.68 | 2023-2025 | Slynd |
| Myovant Sciences INC. | $180.22 | 2022 | |
| Millicent US INC | $170.92 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Dendreon Pharmaceuticals LLC | $163.07 | 2021-2022 | |
| Urogen Pharma, INC. | $121.93 | 2021 | |
| Abbvie INC. | $121.50 | 2021-2023 | |
| Janssen Biotech, INC. | $116.34 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $109.80 | 2023 | Rexulti |
| Boston Scientific Corporation | $109.59 | 2021 | |
| Pfizer INC. | $99.72 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $96.31 | 2021-2022 | |
| Shield Therapeutics INC | $93.90 | 2023-2025 | Accrufer |
| Antares Pharma, INC. | $82.64 | 2021-2022 | |
| Clarus Therapeutics INC. | $67.36 | 2021 | |
| Coloplast Corp | $48.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.70 | 2022 | |
| Urovant Sciences INC | $32.44 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $23.33 | 2023 | Gemtesa |
| Scynexis, INC. | $21.02 | 2022 | |
| Lilly USA, LLC | $19.95 | 2024 | Zepbound |
| Tolmar Pharmaceuticals, INC. | $15.36 | 2022 | |
| Agile Therapeutics, INC. | $14.66 | 2022 | |
| Therapeuticsmd, INC. | $13.99 | 2022 | |
| Blue Earth Diagnostics | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.